Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

Circulation
Thomas A ZelnikerMarc S Sabatine

Abstract

Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic agents that also reduce cardiovascular risk. The relative benefits in patients with and without established atherosclerotic cardiovascular disease for different outcomes with these classes of drugs remain undefined. We performed a systematic review and trial-level meta-analysis of GLP1-RA and SGLT2i cardiovascular outcomes trials using the PubMed and EMBASE databases (Excerpta Medica Database). The primary outcomes were the composite of myocardial infarction, stroke, and cardiovascular death (MACE); hospitalization for heart failure; and progression of kidney disease. In total, data from 8 trials and 77 242 patients, 42 920 (55.6%) in GLP1-RA trials, and 34 322 (44.4%) in SGLT2i trials, were included. Both drug classes reduced MACE in a similar magnitude with GLP1-RA reducing the risk by 12% (hazard ratio [HR], 0.88; 95% CI, 0.84-0.94; P<0.001) and SGLT2i by 11% (HR, 0.89; 95% CI, 0.83-0.96; P=0.001). For both drug classes, this treatment effect was restricted to a 14% reduction in those with established atherosclerotic cardiovascular disease (HR, 0.86; 95% CI, 0.80-0.93; ...Continue Reading

References

Jun 22, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
May 16, 2009·Journal of the American Society of Nephrology : JASN·Toshiharu NinomiyaUNKNOWN ADVANCE Collaborative Group
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Sep 25, 2014·Diabetes Care·Katherine R TuttleMark E Molitch
Jan 4, 2015·BMJ : British Medical Journal·Larissa ShamseerUNKNOWN PRISMA-P Group
May 7, 2015·The Lancet. Diabetes & Endocrinology·Esteban PorriniUNKNOWN ERA-EDTA diabesity working group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jun 28, 2016·Cell Metabolism·Daniel J Drucker
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
May 27, 2017·Journal of the American College of Cardiology·Naveed SattarJames L Januzzi
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 31, 2017·The New England Journal of Medicine·Johannes F E MannUNKNOWN LEADER Steering Committee and Investigators
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Dec 10, 2017·The Lancet. Diabetes & Endocrinology·M Angelyn BethelUNKNOWN EXSCEL Study Group
Jun 26, 2018·The Lancet. Diabetes & Endocrinology·Vlado PerkovicBruce Neal
Aug 5, 2018·Journal of the American College of Cardiology·Thomas A Zelniker, Eugene Braunwald
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators

❮ Previous
Next ❯

Citations

Jun 18, 2019·Circulation·Subodh VermaMikhail Kosiborod
Jul 5, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·Naveed Sattar
Aug 14, 2019·Expert Opinion on Investigational Drugs·Ernest AdeghateErnest A Adeghate
Sep 10, 2019·Hypertension·Michel AziziJean-Sébastien Hulot
Sep 10, 2019·Diabetes, Obesity & Metabolism·Dario GiuglianoKatherine Esposito
Dec 6, 2019·European Heart Journal·Anders JorsalJens Meldgaard Bruun
Dec 10, 2019·Current Opinion in Nephrology and Hypertension·Josselin Nespoux, Volker Vallon
Feb 6, 2020·Diabetes, Obesity & Metabolism·John R PetrieIan W Campbell
Feb 25, 2020·European Journal of Preventive Cardiology·Justin Parizo, Kenneth W Mahaffey
Jan 10, 2020·Future Cardiology·Dalal Y Al-Bazz, John Ph Wilding
Feb 27, 2020·Journal of the Chinese Medical Association : JCMA·Chern-En ChiangTze-Fan Chao
Oct 22, 2019·Endocrine Reviews·Yuliya LytvynDavid Z I Cherney
Apr 30, 2020·ESC Heart Failure·Atsushi TanakaUNKNOWN CANDLE Trial Investigators
Jan 17, 2020·Cardiovascular Endocrinology & Metabolism·Jenifer M Brown, Brendan M Everett
Nov 13, 2019·Current Opinion in Nephrology and Hypertension·Michaël J B van Baar, Daniël H van Raalte
Nov 11, 2019·Journal of Diabetes Investigation·Ko Hanai, Tetsuya Babazono
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Jul 16, 2020·BMJ Open Diabetes Research & Care·Giuseppe PennoUNKNOWN Renal Insufficiency And Cardiovascular Events (RIACE) Study Group
Jul 11, 2020·Current Opinion in Cardiology·Kershaw V Patel, Muthiah Vaduganathan
Jul 3, 2020·The Journal of Clinical Endocrinology and Metabolism·Ilaria CavallariFrancesco Grigioni
May 23, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Kamlesh KhuntiAslam Amod
Aug 30, 2019·Cardiovascular Diabetology·Yue FeiBernard Man Yung Cheung
Sep 15, 2020·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Vikas S SridharDavid Z Cherney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.